Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases

Table 2 Correlations of VEGFR-3 expression at differenr tumor location with clinical parameters

Factors	N	I-VEGFR-3		P-VEGFR-3
		N (%)	P	N (%)	P
VEGF-A expression			0.107		0.067
Low	44	16(36.36)		15(34.09)
High	79	18(22.78)		40(50.63)
VEGF-C expression			0.795		< 0.001
Low	42	11(26.19)		9 (21.43)
High	81	23(28.40)		46(56.79)
VEGF-D expression			0.968		0.043
Low	72	20(27.78)		27(37.50)
High	51	14(27.45)		28(54.90)
P-LVD			0.813		<0.001
<14	60	16(26.67)		10(16.67)
≥ 14	63	18(28.57)		45(71.43)
I-LVD			0.412		0.153
<8	58	14(24.14)		22(37.93)
≥ 8	65	20(30.77)		33(50.77)
Lymph node metastasis			0.934		0.190
Negative	55	19(34.55)		21(38.18)
Positive	68	15(22.06)		34(50.00)
LVI			0.681		0.003
Negative	76	22(28.95)		26(34.21)
Positive	47	12(25.53)		29(61.70)
VI			0.387		0.448
Negative	87	26(29.89)		37(42.53)
Positive	36	8 (22.22)		18(50.00)

Abbreviation: LVD: lymphatic vessel density; LVI: lymphatic vessel invasion; VI: venous invasion; I-VEGFR-3: VEGFR-3 positive expression in the tumor center; P-VEGFR-3: VEGFR-3 positive expression at the tumor periphery.

ISSN: 1471-2407